Bay-substituted perylenediimides as phototherapeutic agents

Resumen del póster presentado a la XXXVIII Reunión Bienal de la Real Sociedad Española de Química, celebrada en el Palacio de Congresos de Granada, del 27 de junio al 30 de junio de 2022.
Perylenediimes (PDIs) are very interesting compounds due to their outstanding electrooptical properties, high fluorescence quantum yields, and huge versatility in their synthetic chemistry. Although PDIs are mainly used in optoelectronic applications, the number of biological studies using PDIs has been growing in the last few years. Here, we report on the synthesis and biological studies of two new families of PDIs as phototherapeutic agents. (Figure 1: a) Imidazolium-PDI, b) [AgPy2(PPh3)]-PDI). Thus, we have prepared water-soluble PDIs based on imidazolium salts as photosensitizes to generate singlet oxygen (1O2), which plays a key role in photodynamic therapy. Internalization and cytotoxicity assays were carried out in HeLa and SHSY5Y human neuroblastoma cells lines. On the other hand, taking advantage of the medicinal potential of some metals, we have synthesized new PDIs linked to silver and copper complexes to study their behavior as metallodrugs. Biological assays were also carried out in HeLa cells line.
This research was supported by the European Regional Development Fund “A way to make Europe” and the Spanish Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (PID2019-109200GB-I00 and RED2018-102471-T).